L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002230:Carbidopa / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000517:prevention & control; D009325:Nausea / Q000517:prevention & control; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D011187:Posture; D014839:Vomiting / Q000517:prevention & control
D006834:Hydrazines; D010919:Placebos; D007980:Levodopa; D002230:Carbidopa